Sanofi/Regeneron asthma trial casts doubt on IL-33 class prospectsThe good news for Sanofi and Regeneron is that their interleukin-33-targeting drug seems to work in asthma. The Share XSanofi/Regeneron asthma trial casts doubt on IL-33 class prospectshttps://pharmaphorum.com/news/sanofi-regeneron-asthma-trial-casts-doubt-il-33-class-prospects/
